Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to ...
Pfizer (PFE -0.60%) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news.
Earlier this year, all three major indexes -- the S&P 500, the Nasdaq, and the Dow Jones Industrial Average -- slid as President Donald Trump announced his plan to impose tariffs on imports. Investors worried this would result in higher costs for U.S. companies as they import their goods made abroad -- and this might sink earnings.
Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is considered safe by Seeking Alpha. Technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Dividend stocks excel in delivering passive income and total returns through reinvestment over five years. These dividend stocks offer 5%+ yields with strong coverage and buy ratings to build resilient portfolios.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.